Market
Additive Manufacturing Adhesives & Sealants Aerospace Agriculture Animal Nutrition & Health Automotive & Transportation Battery Building, Construction & Infrastructure Catalysts Chemical Industry Circular Economy Coatings, Paints & Printing Composites Consumer Goods & Lifestyle Electronics & Telecommunications Energy, Environment & Utilities Food & Beverage Green Hydrogen Home Care & Cleaning Industrial Manufacturing & Machinery Lubricants & Lubricant Additives Medical Devices Metals & Mining Oil & Gas, Petrochemicals Personal Care & Beauty Pharma & Biopharma Plastics & Rubber Pulp, Paper & Packaging Textiles, Leather & Nonwovens
About Evonik
What drives us
We go beyond Purpose Innovation Circularity BVB Partnership History
Structure & Organization
Executive Board Supervisory Board Segments Business Lines ESHQ Procurement Governance & Compliance Facts & Figures General Conditions of Sale and Delivery (GTC)
Business Lines Career Investor Relations
Fahnen flattern vor der Evonik Hauptverwaltung an der Rellinghauser Straße 11 in Essen, DeutschlandFlags flutter in front of Evonik's headquarters at Rellinghauser Strasse 11 in Essen, Germany
SHARE
Press Release
Back
Products

August 01, 2025

Evonik appoints Guido Skudlarek as new head of Health Care business line

Dr. Guido Skudlarek, President Region Americas at Evonik, will assume leadership of Evonik’s Health Care business line as of August 1, succeeding Yann d’Hervé.

Skudlarek studied industrial engineering in Kaiserslautern and London and earned his doctorate from the University of Bayreuth. He began his career in 2001 at McKinsey & Company in Cologne. He joined Evonik in 2013 as Head of the Administration Excellence Program Office.

Since then, he has held several key leadership roles, including VP of the Special Oxides and VP of the Specialty Silica product lines, where he played a pivotal role in the acquisition of Huber Silica. In 2020, he became Head of Operational Excellence before being appointed Regional President Americas in 2024.

With his broad experience in strategy, operations, and international business leadership, Skudlarek is well-positioned to drive the continued growth and innovation of the Health Care business line.

Evonik Health Care partners with the world’s pharmaceutical, medical, and nutritional companies to transform complexity into value. With a broad and versatile portfolio of high-quality ingredients, delivery systems, and contract services, Evonik Health Care generates distinctive outcomes that advance health and well-being.

Alternative image

Evonik: Leading beyond chemistry

Evonik goes beyond the boundaries of chemistry with its combination of innovative strength and leading technological expertise. The global chemical company, headquartered in Essen, Germany, is active in more than 100 countries and generated sales of €15.2 billion and earnings (adjusted EBITDA) of €2.1 billion in 2024. The common motivation of the approximately 32,000 employees: to provide customers with a decisive competitive advantage with tailor-made products and solutions as a superforce for industry, thereby improving people's lives. In all markets. Every day.

About Custom Solutions

The Custom Solutions segment focuses on innovation-driven, tailor-made solutions for customers in specific growth markets. These solutions include additives for coatings, adhesives and sealants, polyurethane foams and lubricants, catalysts, and ingredients for the cosmetics, cleaning and pharmaceutical industries. In 2024, the segment generated sales of €5.7 billion with around 7,000 employees.

Disclaimer

In so far as forecasts or expectations are expressed in this release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.